HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Black Diamond Therapeutics (NASDAQ:BDTX) and increased the price target from $11 to $12.
March 18, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Black Diamond Therapeutics' stock rating was reaffirmed as Buy by HC Wainwright & Co., with a raised price target from $11 to $12.
The reiteration of a Buy rating combined with an increased price target typically signals analyst confidence in the company's future performance, potentially leading to positive investor sentiment and a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100